ZMB Member Katharina Fleischhauer
ZMB Member
Katharina Fleischhauer
Next ZMB-Member
Prof. Dr. Katharina Fleischhauer
Director of:
Institute for Experimental Cellular TherapyUniversity Hospital Essen
Hufelandstraße 55
45122 Essen
- +49 201 723 4583
- Website
- Press Releases
- Selected Publications
- Publication Metrics
-

- ZMB Research Program
Immunology, Infectious Diseases and Transplantation
Research Overview
Focus
The Institute for Experimental Cellular Therapy is dedicated to the transplantation of allogeneic tissues, in particular of hematopoietic stem cells (HSC). HSC transplantation represents the only possibility of definitive cure for many patients affected by tumors of the blood system, such as leukemia, and its clinical application is increasing around the world. Besides offering diagnostic services for allogeneic HSC transplantation, the Institute for Experimental Cellular Therapy is focused on translational research aimed at unraveling the biological mechanisms underlying the clinical success or failure of allogeneic HSC transplantation.
- Cellular and humoral alloreactivity and its role in transplantation
- Molecular and functional polymorphism of the HLA system and immune-related genes
Selected Publications
-
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemiaIn: Blood, Vol. 145, 2025, Nr. 17, pp. 1943 – 1956
-
Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblingsIn: Leukemia, Vol. 39, 2025, Nr. 10, pp. 2523 – 2532DOI (Open Access)
-
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDSIn: Blood, Vol. 144, 2024, Nr. 16, pp. 1747 – 1751
-
A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantationIn: Blood, Vol. 140, 2022, Nr. 6, pp. 659 – 663DOI (Open Access)
-
Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DMIn: Blood, Vol. 137, 2021, Nr. 7, pp. 923 – 928DOI (Open Access)
-
Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemiaIn: Leukemia, Vol. 35, 2021, Nr. 2, pp. 585 – 594
-
External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors failsIn: Blood, Vol. 135, 2020, Nr. 16, pp. 1386 – 1395DOI (Open Access)
-
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantationIn: Nature Medicine, Vol. 25, 2019, Nr. 4, pp. 603 – 611DOI (Open Access)
-
A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCTIn: Blood, Vol. 130, 2017, Nr. 10, pp. 1270 – 1273
-
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children : a retrospective analysisIn: The Lancet Haematology, Vol. 4, 2017, Nr. 7, pp. e325 – e333DOI, Online Full Text (Open Access)
-
HLA-DP in unrelated hematopoietic cell transplantation revisited : Challenges and opportunitiesIn: Blood, Vol. 130, 2017, Nr. 9, pp. 1089 – 1096DOI (Open Access)
-
Prognostic mutations in myelodysplastic syndrome after stem-cell transplantationIn: The New England Journal of Medicine, Vol. 376, 2017, Nr. 6, pp. 536 – 547DOI (Open Access)
-
T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genesIn: Gut, Vol. 66, 2017, Nr. 3, pp. 454 – 463DOI (Open Access)
-
Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCTIn: Blood, Vol. 128, 2016, Nr. 1, pp. 120 – 129DOI (Open Access)
-
Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHDIn: Blood, Vol. 128, 2016, Nr. 15, pp. 1979 – 1986DOI (Open Access)
-
HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia : A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)In: Blood, Vol. 126, 2015, Nr. 23, pp. 399
-
HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell DynamicsIn: Blood, Vol. 126, 2015, Nr. 23, pp. 743
-
Immunogenetics of HLA-DP--A New View of Permissible MismatchesIn: The New England Journal of Medicine, Vol. 373, 2015, Nr. 7, pp. 669 – 672
-
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantationIn: Leukemia, Vol. 29, 2015, Nr. 5, pp. 1143 – 1152
-
Investigating Effect of Genetic Admixture and Donor/Recipient Genetic Disparity on Transplant OutcomesIn: Blood, Vol. 126, 2015, Nr. 23, pp. 3229
-
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donorsIn: Leukemia, Vol. 29, 2015, Nr. 2, pp. 396 – 405
-
The Functional Distance Between Mismatched HLA-DPB1 Increases Risks of Relapse and Mortality after Unrelated Donor Hematopoietic Cell Transplantation for AML, ALL and MDS : A Refinement of the T Cell Epitope Group Algorithm for Permissive MismatchesIn: Blood, Vol. 126, 2015, Nr. 23, pp. 4288
-
Acute Myeloid Leukemia Relapses after Allogenenic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell CostimulationIn: Blood, Vol. 124, 2014, Nr. 21, pp. 427
-
Backtracking Leukemia Clonal Evolution from Post-Transplantation Relapse to Initial Diagnosis to Identify Founder Mutations and Mechanisms of Immune EvasionIn: Blood, Vol. 124, 2014, Nr. 21, pp. 1185
-
Matching of MHC Class I Chain-Related Genes a and B Is Associated with Reduced Incidence of Severe Acute Graft-Versus-Host Disease after Unrelated Hematopoietic Stem Cell TransplantationIn: Blood, Vol. 124, 2014, Nr. 21, pp. 664
